Faeth Therapeutics, Inc reports results for the quarter ended June 30 - Earnings Summary

Faeth Therapeutics

04/08/2026 13:51

Faeth Therapeutics, Inc FTH.OQ reported a quarterly adjusted loss of $2.84​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of $-3.91.  The mean expectation of nine analysts for the quarter was for a loss of $3.05 per share. Wall Street expected results to range from $-10.07 to -46 cents per share.
Reported revenue was zero​; analysts expected zero. 
Faeth Therapeutics, Inc's reported EPS for the quarter was a loss of $2.84​.
The company reported a quarterly loss of $16.01 million.
Faeth Therapeutics, Inc shares had risen by 9.4% this quarter and gained 156.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had fallen by about 354.9% in the last three months.​ 
In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.
RECOMMENDATIONS
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is  "buy."
Wall Street's median 12-month price target for Faeth Therapeutics, Inc is $55.00, about 50.3% above its last closing price of $27.34
This summary was machine generated from LSEG data August 4 at 12:51 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING
ESTIMATE 
ACTUAL
BEAT, MET, MISSED
Jun. 30 2026 
-3.05
-2.84
Beat
Mar. 31 2026 
-0.62
-28.79
Missed
Dec. 31 2025 
-4.81
-3.74
Beat
Sep. 30 2025 
-4.11
-3.62
Beat